NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.88 +0.86 (+1.10%) GOLD FUTURES
2,392.60 +32.70 (+1.39%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,979.16 +3,439.88 (+7.09%)
Pulmatrix, Inc. (2PU.F)
- PR Newswire
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced publication of, "Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, d
- Simply Wall St.
Pulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)
Pulmatrix ( NASDAQ:PULM ) First Quarter 2024 Results Key Financial Results Revenue: US$5.89m (up 293% from 1Q 2023...
- PR Newswire
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced first quarter financial results for 2024 and provided a corporate update on its development programs.
